[HTML][HTML] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - Iscience, 2021 - cell.com
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
[引用][C] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi… - …, 2021 - ui.adsabs.harvard.edu
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally
infected K18-hACE2 mice - NASA/ADS Now on home page ads icon ads Enable full ADS view …
infected K18-hACE2 mice - NASA/ADS Now on home page ads icon ads Enable full ADS view …
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - iScience, 2021 - kclpure.kcl.ac.uk
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi… - …, 2021 - scholarship.miami.edu
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
[HTML][HTML] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - iScience, 2021 - cell.com
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
[PDF][PDF] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - scholar.archive.org
Since the onset of the current COVID-19 pandemic, high priority is given to the development
of neutralizing antibodies, as a key approach for the design of therapeutic strategies to …
of neutralizing antibodies, as a key approach for the design of therapeutic strategies to …
[HTML][HTML] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - iScience, 2021 - ncbi.nlm.nih.gov
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - bioRxiv, 2021 - biorxiv.org
Since the onset of the current COVID-19 pandemic, high priority is given to the development
of neutralizing antibodies, as a key approach for the design of therapeutic strategies to …
of neutralizing antibodies, as a key approach for the design of therapeutic strategies to …
[HTML][HTML] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - 2021 - europepmc.org
Since the onset of the current COVID-19 pandemic, high priority is given to the development
of neutralizing antibodies, as a key approach for the design of therapeutic strategies to …
of neutralizing antibodies, as a key approach for the design of therapeutic strategies to …